Sarepta Therapeutics Inc
(NAS:SRPT)
$
114.8
0.48 (0.42%)
Market Cap: 10.97 Bil
Enterprise Value: 11.06 Bil
PE Ratio: 74.55
PB Ratio: 8.98
GF Score: 85/100 
Sarepta Therapeutics Inc at RBC Global Healthcare Conference (Virtual) Transcript
May 19, 2020 / 06:30PM GMT
Release Date Price:
$145.46
(-0.89%)
Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director
Good afternoon, everyone.
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Good afternoon, everyone, and thanks for joining us. It's Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets. We're really pleased to have with us Sarepta Therapeutics, represented by their CEO, Doug Ingram. Doug, thanks so much for joining us.
Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director
Thank you for having us, Brian.
Questions & Answers
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
So a lot to cover in a short period of time, but maybe I'll kick it off with maybe one of the latest developments that we've seen in the DMD space which is an update on the gene therapy landscape that we've -- we saw last week. So I'd be interested, coming out of that, what your
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers